{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:17Z","timestamp":1789135937407,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of this study was to present summary data from a serum clozapine proficiency testing scheme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Monthly returns submitted to the LGC Standards clozapine and norclozapine proficiency testing scheme between 2012 and 2024 were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 191 participating laboratories participated, of which 164 reported norclozapine results. From 2013 to 2024, the number of returns per distribution was 85. The proportion of laboratories using liquid chromatography\u2013mass spectrometry increased over time and reached 74% in 2024, while the use of high-performance liquid chromatography decreased. Thirteen distributions contained neither analyte; however, 76 returns (6.8%) reported detectable clozapine concentrations (median 10.4, range 0.01\u2013518.73 mcg L\n                      <jats:sup>\u22121<\/jats:sup>\n                      ). In 22 distributions, clozapine concentrations &gt;10 mcg L\n                      <jats:sup>\u22121<\/jats:sup>\n                      (median 151.63, range 30.3\u20132175.25 mcg L\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) were detected but reported as \u201c0\u201d or below the lower limit of quantification. Comparable findings were observed for norclozapine. No temporal differences in quantitative performance, assessed using z-scores, were observed between analytical methods. Median clozapine z-scores were further from zero when clozapine alone was measured than when both clozapine and norclozapine were measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Increased use of liquid chromatography\u2013mass spectrometry was not associated with improved analytical performance for clozapine or norclozapine. Method validation should include assessment of potential interference from metabolites and coadministered drugs. Unexpected results require repeat analysis or repeat sampling when clinically feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001438","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:01:10Z","timestamp":1769144470000},"page":"651-660","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine and N-Desmethylclozapine (Norclozapine) Proficiency Testing Data, 2012\u20132024"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-7886","authenticated-orcid":false,"given":"Lewis","family":"Couchman","sequence":"first","affiliation":[{"name":"Analytical Services International Ltd, St. George's\u2014University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1686-2760","authenticated-orcid":false,"given":"Karen","family":"Morgan","sequence":"additional","affiliation":[{"name":"LGC Standards Proficiency Testing, Bury, Lancashire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-9741","authenticated-orcid":false,"given":"Susanna","family":"Every-Palmer","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, University of Otago, Wellington, New Zealand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-0653","authenticated-orcid":false,"given":"Alice H. M.","family":"Kim","sequence":"additional","affiliation":[{"name":"Biostatistics Group, Dean's Department, University of Otago, Wellington, New Zealand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-7463","authenticated-orcid":false,"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Precision Medicine, Networked Services, Bessemer Wing, King's College Hospital NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","article-title":"Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia","volume":"28","author":"Rajkumar","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/acps.13228","article-title":"Impact of smoking behavior on clozapine blood levels\u2014a systematic review and meta-analysis","volume":"142","author":"Wagner","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/JCP.0000000000001762","article-title":"Effect of cigarette smoking on clozapine dose and on plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in clinical practice","volume":"43","author":"Flanagan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/JCP.0000000000001736","article-title":"Assessing adherence to clozapine: practical considerations","volume":"43","author":"Flanagan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0043-117891","article-title":"A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology","volume":"51","author":"de Leon","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother Psychosom"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/ph15070817","article-title":"Adverse drug reactions in relation to clozapine plasma levels: a systematic review","volume":"15","author":"Skokou","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1192\/bja.2022.71","article-title":"Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations","volume":"29","author":"Flanagan","year":"2023","journal-title":"BJPsych Adv"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1007\/s00216-013-7361-8","article-title":"A novel approach to quantitative LC-MS\/MS: therapeutic drug monitoring of clozapine and norclozapine using isotopic internal calibration","volume":"405","author":"Couchman","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jalm\/jfab062","article-title":"Multi-site evaluation of immunoassays for antipsychotic drug measurement in clinical samples","volume":"6","author":"Clarke","year":"2021","journal-title":"J Appl Lab Med"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpba.2012.11.044","article-title":"The stability of amitriptyline N-oxide and clozapine N-oxide on treated and untreated dry blood spot cards","volume":"76","author":"Temesi","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/FTD.0000000000000478","article-title":"Clozapine and norclozapine concentrations in paired human plasma and serum samples","volume":"40","author":"Handley","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","volume":"90","author":"Reeves","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R18-20260911","first-page":"e16578","article-title":"Clozapine intoxication in a patient on chronic use with a short-term noncompliance","volume":"13","author":"Khan","year":"2021","journal-title":"Cureus"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.japh.2022.05.013","article-title":"Iatrogenic clozapine intoxication after hospital admission: a case-based rationale for an inpatient pharmacy clozapine monitoring service","volume":"62","author":"Leung","year":"2022","journal-title":"J Am Pharm Assoc"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cca.2012.04.003","article-title":"Variability in the analysis of 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry: the devil is in the detail","volume":"413","author":"Couchman","year":"2012","journal-title":"Clin Chim Acta"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:34Z","timestamp":1789135234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001438","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}